On April 29, the Society co-hosted a roundtable with Merck to discuss the current hypoglycemia landscape and to delve deeper into policy priorities that were identified at our diabetes policy summit last September. The roundtable featured key officials from professional societies, patient advocates, quality improvement organizations, and the federal government, including NIDDK, CDC, and Veteran’s Health Administration. At the meeting, participants discussed various perspectives on hypoglycemia as they relate to the patient experience, research and surveillance, issues in the clinical setting, and quality improvement.
The Society will continue working with Merck and participants at the roundtable on initiatives to increase awareness of hypoglycemia and identify areas for collaboration. Tony McCall, MD, PhD, Endocrine Society Vice President for Clinical Science, was our representative and did a masterful job distilling the issues and providing context for next steps. We will keep members apprised of the follow-up.